{
  "uuid" : "",
  "id" : "Molecular_testing_indication_breast_cancer.v0.0.1",
  "gdl_version" : "2.1",
  "concept" : "gt0001",
  "language" : {
    "original_language" : "ISO_639-1::en"
  },
  "description" : {
    "original_author" : {
      "name" : "Katja Mariko Wilde",
      "email" : "katja-wilde@t-online.de",
      "organisation" : "Cambio CDS",
      "date" : "2025-11-20"
    },
    "lifecycle_state" : "DRAFTED",
    "details" : {
      "en" : {
        "id" : "en",
        "purpose" : "To determine whether molecular analyses are recommended or may be considered for a patient with breast cancer based on the explicit criteria provided in the Swedish National Breast Cancer Care Programme.",
        "keywords" : [
          "molecular",
          "testing",
          "breast",
          "cancer",
          "gene expression"
        ],
        "use" : "Use to evaluate whether specific molecular analyses should be performed in breast cancer care.\nThe guideline identifies indications directly based on recommendations in the Swedish National Breast Cancer Care Programme:\n\nGene expression analysis in postmenopausal, ER+/HER2–, node-negative breast cancer when there is uncertainty about tumor risk categorization prior to cytostatic treatment.\n\nGene expression analysis in postmenopausal patients with ER+/HER2– breast cancer and 1–3 positive lymph nodes with intermediate-risk characteristics (NHG 2, intermediate Ki-67).\n\nOncotype Dx consideration in premenopausal, ER+/HER2–, node-negative disease.\n\nGermline BRCA1/2 testing for patients who may receive PARP inhibitors.\n\nSomatic PIK3CA testing for patients who may receive PI3K inhibitors.\n\nBroad genomic profiling in metastatic breast cancer.",
        "misuse" : "Not to be used for genetic risk assessment of healthy family members.\nNot to be used for recording results of molecular analyses.",
        "copyright" : "© Cambio CDS"
      }
    },
    "other_details" : {
      "references" : "Regionala cancercentrum i samverkan. Nationellt vårdprogram bröstcancer: Kapitel 10 Kategorisering av tumören. Kunskapsbanken, 2025. Available at: https://kunskapsbanken.cancercentrum.se/diagnoser/brostcancer/vardprogram/kategorisering-av-tumoren2/#chapter-10-6-Molekylara-analyser",
      "en" : "A clinical decision rule used to determine when molecular analyses should be performed in patients with breast cancer, according to the Swedish National Breast Cancer Care Programme."
    }
  },
  "definition" : { },
  "ontology" : {
    "term_definitions" : {
      "en" : {
        "id" : "en",
        "terms" : {
          "gt0001" : {
            "id" : "gt0001",
            "text" : "Molecular Testing Indication for Breast Cancer",
            "description" : "A clinical decision rule used to determine when molecular analyses should be performed in patients with breast cancer, according to the Swedish National Breast Cancer Care Programme."
          }
        }
      }
    }
  }
}